OD Roundtable Part 1: The Progression, Prevalence and Diagnosis of Keratoconus

OD Roundtable Part 1 The Progression Prevalence and Diagnosis of Keratoconus
Media formats available:
Details
Presenters
  • Overview

    Drs. Barry Eiden, Melissa Barnett, Mile Brujic, Gloria Chiu, John Gelles, and Andy Morgenstern describe keratoconus, risk factors associated with the disease, and key parameters of keratoconus progression. They discuss the incidence and prevalence of keratoconus with various patient groups, as well as the standard diagnostic test criteria that should be used to identify keratoconus patients.


    This activity is supported by an unrestricted educational grant from Avellino.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Define etiology and progression of keratoconus, understand how refractive surgery can exacerbate these conditions, and review the impact this has on visual outcomes and quality of life
    • Describe the prevalence of the refractive surgery patients developing keratoconus in various patient populations
    • Accreditation

      This video has no credit associated with it.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      S. Barry Eiden, OD, FAAO

      S. Barry Eiden, OD, FAAO

      Program Director
      President and Medical Director
      North Suburban Vision Consultants
      Deerfield, Illinois
      Co-founder of the International
      Keratoconus Academy of
      Eye Care Professionals


      Melissa Barnett, OD, FAAO, FSLS, FBCLA

      Melissa Barnett, OD, FAAO, FSLS, FBCLA

      Principal Optometrist
      University of California, Davis, Eye Center
      Sacramento, CA


      Mile Brujic, OD, FAAO

      Mile Brujic, OD, FAAO

      Partner
      Premier Vision Group
      Bowling Green, OH


      Gloria Chiu, OD, FAAO

      Gloria Chiu, OD, FAAO

      Associate Professor of Clinical
      Ophthalmology
      USC Roski Eye Institute
      University of Southern California
      Keck School of Medicine
      Los Angeles, CA


      John D. Gelles, OD

      John D. Gelles, OD

      Director
      Specialty Contact Lens Division
      Cornea and Laser Eye Institute (CLEI)
      and the CLEI Center for Keratoconus
      Teaneck, New Jersey
      Assistant Clinical Professor
      Rutgers New Jersey Medical School
      Newark, NJ


      Andrew S. Morgenstern, OD, FAAO

      Andrew S. Morgenstern, OD, FAAO

      Vision Center of Excellence
      Walter Reed National Military
      Medical Center
      Bethesda, Maryland


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

      The following faculty/staff members have the following financial relationships with commercial interests:

      S. Barry Eiden, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Speaker’s Bureau: Avellino, Glaukos, Oculus, and Oprovve. Grant/Research Support: Oculus.

      Melissa Barnett, OD, FAAO, FSLS, FBCLA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board: Azura, Bruder, Cooper Vision, Dompe, Everyday Contacts, EyeEco, Mojo Vision, Novartis, Ocusoft, Oyster Point,  Percept, and Raayonnova. Advisory Board/Consultant: Visus Therapeutics. Advisory Board/Speaker's Bureau: AAB, Acculens, Allergan, Bausch + Lomb, Contamac, Gas Permeable Lens Institute, JJVC Vistakon, RVL Pharmaceuticals, Scleral Lense Education Society, Synergeyes, Tangible Science, Tarsus. Speaker's Bureau: BCLA, Science Based Health, Sjogren's Syndrom Foundation, and STAPLE Program.

      Mile Brujic, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Akorn, Alcon Vision, Allergan, Bausch + Lomb Health, Blephex, Contamac, CSEye, Eyevance, Horizon Therapeutics, Kala Pharmaceuticals, Novartis, Sun Pharmaceutical Industries, VMax Vision, and Zea Vision. Speaker’s Bureau: Allergan, Bausch + Lomb Health, Kala Pharmaceuticals, Novartis, Optovue, Sun Pharmaceutical Industries, and Zea Vision. Grant/Research Support: Contamac.

      Gloria Chiu, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Avedro/Glaukos and Visionary.

      John D. Gelles, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Avedro, Avellino, Boston Sight, Blanchard Labs, Bausch + Lomb, Contamac, Glaukos, Oculus, Synergeyes, and Visionix. Devices: Boston Sight, Blanchard Labs, Oculus, and Ovitz. Grant/Research Support: Avedro, Avellino, Alcon Vision, CorneaGen, Glaukos, Oculus, and Ovitz. Speaker’s Bureau and Advisory Board: Gas Permeable Labs Institute and International Keratoconus Academy.

      Andrew S. Morgenstern, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: American Optometric Association. Grant/Research Support: International Keratoconus Academy. Speaker’s Bureau: Alcon Vision, Allergan, Glaukos, and Johnson & Johnson Vision.   

      All quotes from Dr. Morgenstern are his personal opinion only. It does not reflect the opinion of the US Department of Defense, Defense Health Agency, Department of Veterans Affairs or any other US governmental organization or agency.

      The Evolve and The Fundingsland Group planners have no financial relationships with commercial interests. 

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Avellino.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free